PROCEPT BioRobotics Corp (PRCT)
60.36
-2.43
(-3.87%)
USD |
NASDAQ |
May 08, 16:00
60.42
+0.06
(+0.10%)
After-Hours: 20:00
PROCEPT BioRobotics Research and Development Expense (Quarterly): 13.08M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 13.08M |
| December 31, 2023 | 14.50M |
| September 30, 2023 | 11.60M |
| June 30, 2023 | 11.61M |
| March 31, 2023 | 10.74M |
| December 31, 2022 | 9.682M |
| September 30, 2022 | 7.582M |
| June 30, 2022 | 6.706M |
| Date | Value |
|---|---|
| March 31, 2022 | 5.011M |
| December 31, 2021 | 5.076M |
| September 30, 2021 | 4.919M |
| June 30, 2021 | 4.476M |
| March 31, 2021 | 4.522M |
| December 31, 2020 | 4.543M |
| September 30, 2020 | 3.893M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.893M
Minimum
Sep 2020
14.50M
Maximum
Dec 2023
7.863M
Average
6.706M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Globus Medical Inc | 57.27M |
| Glaukos Corp | 30.73M |
| Integra Lifesciences Holdings Corp | 26.96M |
| Intuitive Surgical Inc | 284.50M |
| Masimo Corp | 38.00M |